Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study assessed the clinical impact of four treatment strategies in adults with type 1 diabetes (T1D): real-time continuous glucose monitoring (rtCGM) with multiple daily insulin injections (rtCGM+MDI), rtCGM with continuous subcutaneous insulin infusion (rtCGM+CSII), self-monitoring of blood glucose with MDI (SMBG+MDI), and SMBG with CSII (SMBG+CSII). RESEARCH DESIGN AND METHODS: This 3-year, nonrandomized, prospective, real-world, clinical trial followed 94 participants with T1D (rtCGM+MDI, n = 22; rtCGM+CSII, n = 26; SMBG+MDI, n = 21; SMBG+CSII, n = 25). The main end points were changes in A1C, time in range (70–180 mg/dL [3.9–10 mmol/L]), time below range (<70 mg/dL [<3.9 mmol/L]), glycemic variability, and incidence of hypoglycemia. RESULTS: At 3 years, the rtCGM groups (rtCGM+MDI and rtCGM+CSII) had significantly lower A1C (7.0% [53 mmol/mol], P = 0.0002, and 6.9% [52 mmol/mol], P < 0.0001, respectively), compared with the SMBG+CSII and SMBG+MDI groups (7.7% [61 mmol/mol], P = 0.3574, and 8.0% [64 mmol/mol], P = 1.000, respectively), with no significant difference between the rtCGM groups. Significant improvements in percentage of time in range were observed in the rtCGM subgroups (rtCGM+MDI, 48.7–69.0%, P < 0.0001; and rtCGM+CSII, 50.9–72.3%, P < 0.0001) and in the SMBG+CSII group (50.6–57.8%, P = 0.0114). Significant reductions in time below range were found only in the rtCGM subgroups (rtCGM+MDI, 9.4–5.5%, P = 0.0387; and rtCGM+CSII, 9.0–5.3%, P = 0.0235). Seven severe hypoglycemia episodes occurred: SMBG groups, n = 5; sensor-augmented insulin regimen groups, n = 2. CONCLUSIONS: rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical efficacy of CGM has been demonstrated in numerous retrospective studies and RCTs of individuals with T1D regardless of insulin delivery method.156–161”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [157]
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“Daily Injections and Continuous Glucose Monitoring in Diabetes (DIAMOND) trial (8), Skandari and colleagues (27) found that among rtCGM1CSII participants, the total per-person 28-week costs were $8,272 vs.”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“Similar improvements in A1C and hypoglycemia have also been observed in participants using rtCGM with insulin pump therapy (12,13).”
BackgroundHeinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522 · cited 1×
“Significant reductions in severe hypoglycemia have also been observed in patients with type 1 diabetes (T1D) with problematic hypoglycemia who were treated with rtCGM in combination with either MDI (10) or insulin pump therapy (13).”
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“HbA1c, TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90, 91).”
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Self-citation6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Hásková, A., Radovnická, L., Petruželková, L., Parkin, C. G., Grunberger, G., Horová, E., Navrátilová, V., Kádě, O., Matoulek, M., Prázný, M., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0112 · Cited by 146
Self-citationContinuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology
Galindo, R. J., & Aleppo, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108502 · Cited by 133
Phillip, M., Bergenstal, R. M., Close, K. L., Danne, T., Garg, S. K., Heinemann, L., Hirsch, I. B., Kovatchev, B. P., Laffel, L. M., Mohan, V., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0375 · Cited by 135
Self-citationCardona-Hernandez, R., Schwandt, A., Alkandari, H., Bratke, H., Chobot, A., Coles, N., Corathers, S., Goksen, D., Goss, P., Imane, Z., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1674 · Cited by 129
Malahi, A. E., Elsen, M. V., Charleer, S., Dirinck, E. L., Ledeganck, K. J., Keymeulen, B., Crenier, L., Radermecker, R. P., Taes, Y., Vercammen, C., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab688 · Cited by 131
Bergenstal, R. M., Layne, J. E., Zisser, H., Gabbay, R. A., Barleen, N. A., Lee, A. A., Majithia, A. R., Parkin, C. G., & Dixon, R. F. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0396 · Cited by 110
Self-citationDicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01589-3 · Cited by 106
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
Tauschmann, M., Forlenza, G., Hood, K., Cardona‐Hernandez, R., Giani, E., Hendrieckx, C., DeSalvo, D. J., Laffel, L. M., Saboo, B., Wheeler, B. J., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13451 · Cited by 100
Domingo‐Lopez, D. A., Lattanzi, G., Schreiber, L. H. J., Wallace, E. J., Wylie, R., O’Sullivan, J., Dolan, E. B., & Duffy, G. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114280 · Cited by 125
Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified
Anderson, J. E., Gavin, J. R., & Kruger, D. F. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0303 · Cited by 77
“One approach would be to compare the percentage of study subjects who achieved significant clinical benefit, as was done in the recent analyses.(7,12,14,31) This approach provides both an opportunity to identify and elucidate the characteristics of those patients who are most (or least) suited for the CGM use and the…”
ResultMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease
Klupa, T., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Gumprecht, J., Myśliwiec, M., Szadkowska, A., Bomba-Opon, D. A., Czajkowski, K., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01431-3 · Cited by 94
“Prospective trials have typically documented these glycemic benefits over periods up to 12 months; however, the COMISAIR prospective study demonstrated a persistent effect of the Dexcom G4 real-time CGM system over 3 years in adults with T1DM [14].”
BackgroundFantasia, K. L., Wirunsawanya, K., Lee, C., & Rizo, I. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821995810 · Cited by 62
Jiao, Y., Lin, R., Hua, X., Churilov, L. P., Gaca, M., James, S., Clarke, P., O'Neal, D. N., & Ekinci, E. I. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.369 · Cited by 80
“Six studies assessed a specific subset of patients: (1) patients with suboptimal glycaemic management at baseline; (2) those who are at high risk of hypoglycaemia episodes; and (3) those with HbA1c <7%28 or (4) those aged >25 years.”
BackgroundGolledge, J., Fernando, M. E., Lazzarini, P. A., Najafi, B., & Armstrong, D. G. (2020) · Sensors · doi:10.3390/s20164527 · Cited by 71
“Recent meta-analyses of randomised trials comparing self-monitoring and the continuous automated monitoring of glucose in people with type 2 diabetes suggest that continuous monitoring facilitates better glycaemic control [61,63–65].”
BackgroundMonnier, L., Colette, C., & Owens, D. R. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101225 · Cited by 63
Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations
Bailey, T. S., & Alva, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0236 · Cited by 56
Visser, M. M., Charleer, S., Fieuws, S., Block, C. E. M. D., Hilbrands, R., Huffel, L. V., Maes, T., Vanhaverbeke, G., Dirinck, E. L., Myngheer, N., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00352-7 · Cited by 55
Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management
Munshi, M. N. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0111 · Cited by 63
Seyed Ahmadi, S., Westman, K., Pivodic, A., Ólafsdóttir, A. F., Dahlqvist, S., Hirsch, I. B., Hellman, J., Ekelund, M., Heise, T., Polonsky, W., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2606 · Cited by 51
“A recent study that compared adding CGM to MDI and pump treatment showed relatively similar effects with respect to HbA1c and time spent in hypoglycemia when patients fully performed insulin dosing (12).”
BackgroundMehmood, S., Ahmad, I., Arif, H., Ammara, U. E., & Majeed, A. (2020) · Applied System Innovation · doi:10.3390/asi3030031 · Cited by 58
Wang, Y., Yu, H., Wang, L., Zhang, L., Liu, J., Chen, D., Yang, J., Ouyang, C., Hu, J., Feng, J., et al. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122885 · Cited by 53
Divan, V., Greenfield, M., Morley, C. P., & Weinstock, R. S. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820978769 · Cited by 53
Roze, S., Isitt, J., Smith-Palmer, J., Javanbakht, M., & Lynch, P. (2020) · Diabetes Care · doi:10.2337/dc19-2213 · Cited by 43
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
“For diabetic macrovascular complications, cohort studies have reported that short-term GV and the TIR, which are assessed by SMBG and CGM, are associated with CVD and cardiovascular death (71, 72, 74).”
BackgroundInfluentialChow, K. W., Kelly, D. J., Rieff, M. C., Skala, P. A., Kravets, I., Charitou, M. M., Morley, E. J., Gupta, R., & Miller, J. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820985263 · Cited by 40
Charleer, S., De Block, C., Nobels, F., Radermecker, R. P., Lowyck, I., Mullens, A., Scarnière, D., Spincemaille, K., Strivay, M., Weber, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1531 · Cited by 39
Schlüter, S., Freckmann, G., Heinemann, L., Wintergerst, P., & Lange, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14467 · Cited by 43
Layne, J. E., Jepson, L. H., Carite, A. M., Parkin, C. G., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0197 · Cited by 37
Self-citationGarg, S. K., Hirsch, I. B., Repetto, E., Snell‐Bergeon, J. K., Ulmer, B. J., Perkins, C., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15866 · Cited by 42
Galindo, R. J., Parkin, C. G., Aleppo, G., Carlson, A. L., Kruger, D. F., Levy, C. J., Umpierrez, G. E., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0107 · Cited by 38
Self-citationLind, M., Ólafsdóttir, A. F., Hirsch, I. B., Bolinder, J., Dahlqvist, S., Pivodic, A., Hellman, J., Wijkman, M. O., Schwarcz, E., Albrektsson, H., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1468 · Cited by 44
Aleppo, G., Hirsch, I. B., Parkin, C. G., McGill, J., Galindo, R., Kruger, D. F., Levy, C. J., Forlenza, G. P., Umpierrez, G. E., Grunberger, G., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0268 · Cited by 34
Self-citationEkberg, N. R., Hartvig, N. V., Kaas, A., Møller, J. B., & Adolfsson, P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221104142 · Cited by 36
Continuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD
Galindo, R. J., de Boer, I. H., Neumiller, J. J., & Tuttle, K. R. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04510422 · Cited by 36
Norman, G. J., Paudel, M. L., Parkin, C. G., Bancroft, T., & Lynch, P. M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0525 · Cited by 36
Self-citationJacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
Continuous glucose monitoring for children with hypoglycaemia: Evidence in 2023
Worth, C., Hoskyns, L., Salomon-Estebanez, M., Nutter, P. W., Harper, S., Derks, T. G. J., Beardsall, K., & Banerjee, I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1116864 · Cited by 29
Psoma, O., Makris, M., Tselepis, A. D., & Tsimihodimos, V. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221146808 · Cited by 32
“92 Also, in comparison with inter-mittently scanned CGM, rt-CGMs had induced greater improvements in CV and SD in patients at high risk of hypo-glycemia.”
Acciaroli, G., Welsh, J. B., & Akturk, H. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820982584 · Cited by 27
Warshaw, H. S., Isaacs, D. M., & MacLeod, J. (2020) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721720930183 · Cited by 27
“(3) self-monitoring of blood glucose (SMBG) with MDI, and (4) SMBG with CSII.(26) At 3 years, the people with diabetes who used real-time CGM with MDI or real-time CGM with CSII had significantly lower A1C and significant improvement of percentage of time spent in (glucose) range (TIR) than the 2 groups using SMBG, wi…”
BackgroundMethodInsulinoterapia no diabetes mellitus tipo 1 (DM1)
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-5 · Cited by 59
Gavin, J. R., & Bailey, C. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0211 · Cited by 29
“…of A1C and fructosamine are often used to monitor glycemic status in individuals without chronic kidney disease, these methods are limited in their S-24 GAVIN AND BAILEY utility to predict the risk of acute glycemic events and to assess glycemic control in patients treated with dialysis.”
D’Amico, R. P., Pian, T. M., & Buschur, E. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.006 · Cited by 29
Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care
Unger, J., Kushner, P. R., & Anderson, J. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1744393 · Cited by 28
Utilizing continuous glucose monitoring in primary care practice: What the numbers mean
Edelman, S. V., Cavaiola, T. S., BOEDER, S. C., & Pettus, J. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.013 · Cited by 27
Serné, E. H., Roze, S., Buompensiere, M. I., Valentine, W. J., de Portu, S., & de Valk, H. W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02058-9 · Cited by 27
“Recent data suggest that RT-CGM, specifically hybrid closed loop systems, is more effective than IS-CGM in improving glycemic control, but short-term costs of IS-CGM are approximately half that of a RT-CGM system [13, 17].”
BackgroundIsitt, J. J., Roze, S., Tilden, D., Arora, N., Palmer, A. J., Jones, T. W., Rentoul, D., & Lynch, P. M. (2022) · Diabetic Medicine · doi:10.1111/dme.14831 · Cited by 25
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
Beck, R. W., & Bergenstal, R. M. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0090 · Cited by 23
Beck, S. E., Kelly, C., Price, D. A., & for the COACH Study Group (2021) · Diabetic Medicine · doi:10.1111/dme.14739 · Cited by 27
Time above range for predicting the development of type 2 diabetes
Marco, A., Pazos-Couselo, M., Moreno-Fernández, J., Díez‐Fernández, A., Alonso‐Sampedro, M., Fernández‐Merino, C., González‐Quintela, A., & Gudé, F. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1005513 · Cited by 25
Šumník, Z., Pavlíková, M., Pomahačová, R., Venháčová, P., Petruželková, L., Škvor, J., Neumann, D., Vosáhlo, J., Konečná, P., Čížek, J., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13184 · Cited by 23
“bursement in October 2018 (Figure 5), and mirrors the evidencebased statement that CGM and not CSII (without advanced automatic functions) is the key factor in our effort to achieve the best diabetes control.(4,15) An important predictor of CGM use is center size.”
BackgroundSelf-citationDicembrini, I., Pala, L., Caliri, M., Minardi, S., Cosentino, C., Monami, M., & Mannucci, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14028 · Cited by 22
“The COMISAIR trial suggests that CGM reduces HbA1c, whereas CSII is irrelevant in this respect.(8,12) The data of the COMISAIR trial should not be considered conclusive, because of the small sample size.”
BackgroundResultIntegrating Continuous Glucose Monitoring Into Clinical Practices and Patients' Lives
Hirsch, I. B., & Miller, E. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0233 · Cited by 24
Bratke, H., Margeirsdottir, H. D., Assmus, J., Njølstad, P. R., & Skrivarhaug, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01127-6 · Cited by 20
Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020
van der Linden, J., Welsh, J. B., & Walker, T. C. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0014 · Cited by 19
“…observations from the COMISAIR study, where participants who self-selected to use CGM for glucose monitoring had lower A1C values than those who used SMBG, 7 and the SILVER study that reported on the long-term effects of CGM use on A1C reduction, treatment satisfaction, and hypoglycemic confi-dence.”
Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment
Wright, E. E., & Subramanian, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0191 · Cited by 20
“…after acquisition of a flash CGM. 63 Although studies have demonstrated that persistent daily use of CGM is considered essential for intensive insulin management, 1,2,5,11,12,68,69 intermittent CGM use with non-intensive treatment regimens therapies has also shown significant glycemic improvements.”
Real-world outcomes with different technology modalities in type 1 diabetes
Beato-Víbora, P. I., Gallego-Gamero, F., & Ambrojo-López, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.028 · Cited by 18
William, J., McCluskey, J. T., & Gleeson, N. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.324 · Cited by 21
Gavin, J. R., & Bailey, C. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0057 · Cited by 18
Galindo, R. J., Aleppo, G., Parkin, C. G., Baidal, D. A., Carlson, A. L., Cengiz, E., Forlenza, G. P., Kruger, D. F., Levy, C. J., McGill, J. B., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221144052 · Cited by 19
“17,20,30,36,38 • Significant decreases in %TBR. 17,30,36 • Significant reductions in diabetes-related hospitalizations.”
Self-citationNationally Subsidized Continuous Glucose Monitoring: A Cost-effectiveness Analysis
Pease, A., Zoungas, S., Callander, E. J., Jones, T. W., Johnson, S. R., Holmes-Walker, D. J., Bloom, D. E., Davis, E. A., & Zomer, E. (2022) · Diabetes Care · doi:10.2337/dc22-0951 · Cited by 20
Miller, E. M., & Miller, K. (2024) · Clinical Diabetes · doi:10.2337/cd23-0077 · Cited by 18
Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes: A Narrative Review
Adolfsson, P., Hanås, R., Zaharieva, D. P., Dovč, K., & JENDLE, J. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241248404 · Cited by 19
Glycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Amigó, J., Ortiz-Zúñiga, Á., de Urbina, A. M. O., Sánchez, M., Dos-Santos, M., Abad, M., Cuadra, F., Simó, R., Hernández, C., & Simó-Servat, O. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110730 · Cited by 15
Advances in diabetes technology within the digital diabetes ecosystem
Aktürk, H. K., & Bindal, A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.10-b.s7 · Cited by 22
Roze, S., Isitt, J. J., Smith-Palmer, J., & Lynch, P. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s304395 · Cited by 15
“However, although long-term data are lacking, data from the COMISAIR study suggest that the treatment effects of RTCGM are maintained over a period of at least 3 years.(40) The possibility of a waning in treatment effect over time was not examined; however, a sensitivity analysis was performed in which the magnitude o…”
BackgroundHow use of continuous glucose monitoring can address therapeutic inertia in primary care
Martens, T. W., & Parkin, C. G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2080419 · Cited by 16
“JD’s initial rtCGM data from the past 90 days revealed extremely poor glycemic control as evidenced by her elevated average glucose and %TIR, which was below the established target of >70% [74].”
InfluentialSelf-citationPutting Continuous Glucose Monitoring to Work for People With Type 1 Diabetes
Hood, K. K., DiMeglio, L. A., & Riddle, M. C. (2019) · Diabetes Care · doi:10.2337/dci19-0054 · Cited by 16
“(11) report a follow-up of the Comparison of Sensor Augmented Insulin Regimens (COMISAIR) study (12).”
BackgroundNorman, G. J., Fernandes, J., Nemlekar, P. M., Andrade, S. B., Lupton, L. L., & Berk, A. R. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24255 · Cited by 21
von Kobyletzki, L. B., Ulriksdotter, J., Sukakul, T., Aerts, O., Agner, T., Buhl, T., Bruze, M., Foti, C., Giménez‐Arnau, A. M., Gonçalo, M., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19908 · Cited by 16
Billion, L., Charleer, S., Verbraeken, L., Sterckx, M., Vangelabbeek, K., Block, N. D., Janssen, C., Dessel, K. V., Dirinck, E. L., PEIFFER, F. W., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14527 · Cited by 15
Feasibility study of a prototype extended‐wear insulin infusion set in adults with type 1 diabetes
Kastner, J. R., Venkatesh, N., Brown, K., Muchmore, D. B., Ekinci, E. I., Fourlanos, S., Joseph, J. I., Shafeeq, M., Shi, L., Strange, P., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14685 · Cited by 15
“unexpected hyperglycaemia and/or occlusion can be well above 60%.(18,19) Occlusions are among the main reasons cited in the literature justifying the recommendation to replace an IIS after 3 days.”
BackgroundDowd, R., Jepson, L. H., Green, C. R., Norman, G. J., Thomas, R., & Leone, K. (2023) · JMIR Diabetes · doi:10.2196/43991 · Cited by 14
“CGM is associated with improved glycemic outcomes in people with T1D [1-4] and intensive insulin-treated T2D [5].”
BackgroundJotić, A., Milicic, T. J., Lalic, K. S., Lukić, L., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Gojnić-Dugalić, M., Jeremić, V., & Lalic, N. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00780-7 · Cited by 14
CASTORINO, K. N., Durnwald, C. P., Ehrenberg, S., Ehrhardt, N. M., Isaacs, D., Levy, C. J., Valent, A. M., & Continuous Glucose Monitoring for Gestational Diabetes Management Working Group (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0864 · Cited by 15
Monnier, L., Colette, C., & Owens, D. R. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.06.004 · Cited by 13
The future of telehealth in type 1 diabetes
Cobry, E. C., & Wadwa, R. P. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000745 · Cited by 13
Helleputte, S., Calders, P., Rodenbach, A., Marlier, J., Verroken, C., Backer, T. L. M. D., & Lapauw, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01717-z · Cited by 13
“The increasing use of CGM in T1D care has been a revolution [8], providing insight into different aspects of (shorter-term) glycemic control [9].”
BackgroundKim, J. Y., Ilham, S., Alshannaq, H. A., Pollock, R. F., Ahmed, W., Norman, G. J., Jin, S., & Kim, J. H. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2405293 · Cited by 12
Cutaneous manifestations of diabetes mellitus: a narrative review
Abate, M. C. M. D. O., Aroucha, P. M. T., da Nóbrega, D. V. M., Rocha, I. P. M., Soares, S. D., Reis, A. A., Paliares, I. C., Giuffrida, F. M. A., Dib, S. A., Reis, A. F., et al. (2025) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2025rw1193 · Cited by 18
“(51,52) 53-55) Commonly reported skin lesions include erythema, lipodystrophy (specific to CSII use), subcutaneous nodules, scars, and pruritus.”
Iwase, M., Komorita, Y., Fujii, H., Ohkuma, T., Ide, H., Yoshinari, M., Oku, Y., Higashi, T., Nakamura, U., & Kitazono, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13253 · Cited by 11
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Aleppo, G., Parkin, C. G., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., Umpierrez, G. E., Forlenza, G. P., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0196 · Cited by 11
Self-citationContinuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Is Continuous Glucose Monitoring a Tool, an Intervention, or Both?
Wright, E. E., & Subramanian, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0025 · Cited by 13
Gupta, A. V., Mukherjee, S., Bhadada, S. K., Ram, S., Pal, R., Sachdeva, N. K., & Dutta, P. R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111610 · Cited by 10
All Insulin Pumps Are Not Equivalent: A Bench Test Assessment for Several Basal Rates
Girardot, S., Jacquemier, P., Mousin, F., Rendekeu, C., Hardy, S., & Riveline, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0486 · Cited by 10
“21 We recently introduced a new bench test method that is able to reach high-precision measurement of insulin administration at several BRs, 12 including the lowest levels.”
Metadata
- Authors
- Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., Škrha, J., Parkin, C. G., Svačina, Š., & Prázný, M.
- Affiliations
- Charles University (CZ)
- Oakland University (US)
- 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- CGParkin Communications, Inc., Henderson, NV
- Corresponding author
- Šoupal, Jan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-17
- Volume
- 43
- Issue
- 1
- Pages
- 37-43
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974459507
- Cited by
- 242
- References
- 25
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 42 · 2023: 30 · 2022: 50 · 2021: 46 · 2020: 35 · 2019: 4
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, continuous glucose monitoring, insulin pump therapy, multiple daily insulin injections, self-monitoring of blood glucose, glycemic control, HbA1c, time in range, time below range, glycemic variability, hypoglycemia, adults with type 1 diabetes, insulin delivery method, real-world evidence
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Drug Administration Routes, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Longitudinal Studies, Male, Middle Aged, Blood Glucose Self-Monitoring, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.